17th Congress of the
International Society for Peritoneal Dialysis
VANCOUVER, CANADA | MAY 5-8, 2018

Introduction to the PD clinical trials session.

The challenge of research waste

Martin Wilkie, Sheffield Teaching Hospitals NH

Disclaimer

- This year, I have received honoraria from Fresenius, Baxter and Triomed.

Research waste - the size of the problem?

Paul Glasziou and Iain Chalmers: Is 85% of health research really “wasted”?

January 14, 2016

Our estimate that 85% of all health research is being avoidably “wasted” [Chalmers & Glasziou, 2009] commonly elicits disbelief. Our own first reaction was similar: “that can’t be right?” Not only did 85% sound too much, but given that $200 billion per year is spent globally on health and medical research, it implied an annual waste of $170 billion. That amount ranks somewhere between the GDPs of Kuwait and Hungary. It seems a problem worthy of serious analysis and attention. But how can we estimate the waste?

BMJ blog 2016

Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis

Fewer than half of trials funded by NIH are published in a peer reviewed biomedical journal indexed by Medline within 30 months of trial completion.



Ross JS et al, *BMJ* 2011;344:d7292

Stages in research production that lead to waste



David Moher, Paul Glasziou, Iain Chalmers, Mona Nasser, Patrick M M Bossuyt, Daniël A Korevaar, Ian D Graham, Philippe Ravaud, Isabelle Boutron. www.thelancet.com **Vol 387 April 9, 2016**

Avoidable waste in the production and reporting of research evidence

- Choosing the wrong questions for research
- Doing studies that are unnecessary, or poorly designed
- Failure to publish relevant research promptly, or at all
- Biased or unusable reports of research

PD Clinical Trial Design – goal of the session

To discuss mechanisms that will improve the impact of the PD community to conduct research that delivers benefits for patients, carers and health care teams.

PD Clinical Trial Design Session

Chairs – Robert Quinn & Martin Wilkie

- Questions and outcomes that matter to patients
  Allison Tong
- Study Design for Maximum Impact
  David Johnson
- Opportunities for Registry Design to Contribute High Quality Research
  Mark Lambie
- Working Together with Industry to Answer Key Questions
  James Sloand
- Open discussion & summing up.